GLP1R and hydrops fetalis: The FIGHT (Functional Impact of GLP-1 for HF Treatment) study, which included 300 patients with recently decompensated HFrEF, did not show a superiority of liraglutide over the placebo on HF-related outcomes or functional capacity [81].